1.
Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.(Report)
by Cheng, Yu
European Journal of Clinical Pharmacology, March, 2013, Vol.69(3), p.407(7)
